A researcher would typically draw up the Mod GRF 1-29 first, followed by the Ipamorelin
Originally approved for type 2 diabetes, GLP-1 RAs are now central to evidence-based obesity treatment, with large randomized trials showing significant weight loss and improved glycemic control
Patients who would benefit from semaglutide or tirzepatide can now begin treatment within days rather than months, allowing them to start their weight loss journey on their own timeline
GLP-1 Shaping Up to Be the PD-1 of Obesity Immunotherapies, particularly checkpoint inhibitors PD-1s & PD-L1s, have been transformational for oncology treatments
A thorough clinical assessment, including medical history, current medications, and discussion of treatment goals and expectations, is essential before initiating a GLP-1 plan to ensure appropriateness and safety